瑞舒伐他汀对扩张型心肌病患者心功能及细胞因子的影响  

Effect of Rosuvastatin on Cardiac Function and Cytokines in Patients with Dilated Cardiomyopathy

作　　者：张红艳[1] 赵宁民[1] 池发斌[1] 

机构地区：[1]河南省人民医院,郑州市450003

出　　处：《医药论坛杂志》2009年第4期3-5,共3页Journal of Medical Forum

摘　　要：目的观察瑞舒伐他汀对扩张性心肌病(DCM)心力衰竭患者心功能及血清肿瘤坏死因子(TNF-α)、白细胞介素-6(IL-6)水平的影响。方法选择DCM心力衰竭患者67例,随机分为治疗组(34例)及对照组(33例)。对照组给予常规纠正心力衰竭药物治疗,治疗组在常规治疗基础上加用瑞舒伐他汀10mg,每晚1次。治疗前及治疗6个月后进行心脏彩超检查,测定左心室舒张末内径(LVEDd)、左心室射血分数(LVEF),测定血清TNF-α、IL-6浓度。结果两组患者治疗6个月时LVEDd均较治疗前显著缩小(P<0.05),LVEF较治疗前显著提高(P<0.05)。治疗6个月时治疗组与对照组比较:LVEF较对照组显著提高(P<0.05),LVEDd有进一步缩小趋势,但差异无统计学意义。治疗6个月时,治疗组血清TNF-α[(149.76±1.16)和(177.76±1.39),P<0.05]、IL-6[(24.37±1.45)和3(2.37±1.55),P<0.05]水平较治疗前显著下降,对照组较治疗前无明显变化。结论瑞舒伐他汀可明显改善DCM心力衰竭患者心功能,降低血清TNF-α、IL-6水平,有利于DCM的治疗。Objective To investigate the effect of Rosuvastatin on cardiac function and ser- um levels of tumor necrosis factor-α （ TNF -α） and interleukin - 6 （ IL - 6） in patients with dilated cardiomyopathy（DCM）. Methods Sixty - seven patients with DCM were randomly divided into two groups： Rosuvastatin group （n = 34） and conventional therapy group （n = 33 ）. All patients were treated by conventional therapy. The Rosuvastatin group plus Rosuvastatin 10mg a night for 6 months. Before and after treatment, the left ventricular ejection fraction （LVEF）, left ventricular end - diastolic diameter （LVEDd） were measured by ultrasonic cardiograph and serum lipids, TNF-α and IL - 6 were measured by radioimmunoassay. Results After six months, the LVEDd were significantly lower and LVEF was dramatically higher in all patients （P 〈 0. 05）, the LVEF in Rosuvastatin group were sig- nificantly higher than that in the conventional therapy group （P 〈 0. 05 ）. The serum level of TNF -α [ （ 149.76 ± 1.16） vs（ 177.76 ± 1.39）, P 〈 0. 05 ] and IL - 6 [ （24. 37 ± 1.45 ） vs（32. 37 ± 1.55 ）, P 〈 0. 05） ] were significantly lower in Rosuvastatin group. Conclusion Rosuvastatin can improve cardiac function and decrease serum levels of TNF -α and IL - 6 in Patients with dilated cardiomyopathy.

关 键 词：瑞舒伐他汀 心力衰竭 细胞因子类 

分 类 号：R542.21[医药卫生—心血管疾病]